Test Price
3,000 AED✅ Home Collection Available
Comprehensive Ophthalmic Genetic Disorder Panel in UAE | 3000 AED | DHA Licensed
Executive Summary & Core Metrics
This comprehensive genetic analysis delivers 99.9% diagnostic accuracy for inherited ophthalmic disorders using advanced Next Generation Sequencing, with premium DHA-licensed home collection service operating from 8 AM to 11 PM across Dubai and the UAE.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity achieved via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139) and Next Generation Sequencing (NGS) methodology with full deletion and duplication analysis.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection — adhering strictly to UAE PDPL data privacy protocols (Federal Decree-Law No. 45 of 2021) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for specimen integrity.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation provided by a DHA-licensed Consultant Medical Genetics to correlate genetic findings with your broader ophthalmologic profile.
- Insurance & Support: Direct Billing Verification and immediate pre-test consultation via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The Comprehensive Ophthalmic Genetic Disorder Panel analyzes over 500 genes associated with inherited retinal dystrophies, optic neuropathies, congenital cataracts, and anterior segment dysgenesis, providing a definitive molecular diagnosis where clinical presentation overlaps. This single blood test replaces sequential single-gene testing, streamlining the diagnostic odyssey for UAE families affected by vision loss.
| Feature | Our Test (Premium) | Closest Alternative |
|---|---|---|
| Precision & Depth | Full Gene sequencing via NGS with deletion/duplication analysis (CNV detection). Greater than 99.9% analytical sensitivity. | Targeted mutation panels or single-gene Sanger sequencing. Limited variant detection. |
| Methodology | Next Generation Sequencing (NGS) aligned to updated genome datasets for comprehensive variant interpretation. | Microarray or older genotyping arrays, often missing rare variants. |
| Turnaround Time | 21 Working Days, expedited clinical reporting portal access. | Often 8-12 weeks for multi-step reflex testing to reference labs abroad. |
| Report Actionability | Includes ICD-10-coded diagnosis, genetic counseling notes, and therapeutic trial eligibility. | Limited to variant description without clinical correlation or therapeutic mapping. |
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics, I consider this comprehensive ophthalmic panel an essential diagnostic tool for patients with unexplained visual impairment. A definitive genetic finding can guide gene-specific therapy, inform accurate recurrence risk counseling, and avoid unnecessary invasive investigations. Remember that a negative result does not eliminate a genetic cause; correlation with your complete clinical history, retinal imaging, and electrophysiology remains critical for comprehensive care planning."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Critical Medication Warning
Do not discontinue prescribed ocular or systemic medication without consulting your doctor. Genetic results are not an immediate directive for treatment change and require specialist integration with your current therapeutic regimen.
Safety Exclusion & Emergency Red Flags
- Exclusion Criteria: This test cannot be processed for patients who have undergone allogeneic bone marrow transplantation within the last 6 months, as donor DNA will confound germline results. Active severe leukopenia contraindicating phlebotomy is an absolute exclusion.
- Post-Test Red Flags: If you experience sudden irreversible vision loss, severe eye pain, or symptoms of retinal detachment before or after testing, do not wait for results. Proceed immediately to the nearest emergency department.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License 1143 and complies fully with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-restricted, and processed solely for diagnostic purposes under strict confidentiality agreements.
Patient FAQ & Clinical Guidance
1. Does this panel screen for all causes of childhood blindness in the UAE population?
This Comprehensive Ophthalmic Panel screens for over 500 genes, providing a 92% first-pass diagnostic yield for inherited retinal diseases common in consanguineous populations such as Leber Congenital Amaurosis and Retinitis Pigmentosa, but it does not cover non-genetic prenatal infections. All clinical information disclosed is governed by Federal Decree-Law No. 4 of 2016 on Medical Liability to ensure your safety and rights throughout the diagnostic process.
2. What is the exact home collection protocol for a DNA FTA card in Dubai?
A DHA-licensed phlebotomist arrives at your home between 8 AM and 11 PM and performs a simple, nearly painless finger-prick collection, depositing blood spots directly onto a DNA-stabilizing FTA card for immediate room-temperature storage, in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
3. Could a negative result on this NGS mean my eye disease is still genetic?
Yes, a negative NGS result cannot exclude pathogenic deep intronic variants, mitochondrial heteroplasmy below the detection threshold, or complex structural rearrangements, necessitating potential whole genome sequencing if clinical suspicion remains high. Your Consultant Medical Genetics will review all findings in the context of your full medical history and ophthalmologic workup.
Clinical & Logistical Metadata
| Test Name | Comprehensive Ophthalmic Genetic Disorder Panel |
| Price (AED) | 3000 AED |
| Turnaround Time | 21 Working Days |
| Sample Type / Matrix | Whole Blood (EDTA) or FTA Card Finger-Prick |
| Methodology Used | Next Generation Sequencing (NGS) with CNV Detection |
| ICD-10-CM Code | H35.5 — Hereditary retinal dystrophy |
| LOINC Code | 81303-8 — Inherited retinal disease gene panel |
| DHA Facility License & Laboratory Address Invariants | DHA License: 1143, Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE, Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians